 |
27 Diseases |  |
6 Trials |
|
6 Trials |  |
718 News |  |
| «12345678» |
- | Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial initiation date: Effects of Victoza (clinicaltrials.gov) - Mar 3, 2017
P1, N=72, Active, not recruiting, Sponsor: Profil Institut f
Initiation date: Feb 2015 --> Jul 2015
- |||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: LixiRam: Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan (clinicaltrials.gov) - Feb 8, 2017
P4, N=236, Recruiting, Sponsor: Sanofi
Initiation date: Feb 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial termination: Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients (clinicaltrials.gov) - Jan 30, 2017
P2, N=2, Terminated, Sponsor: Sanofi
Not yet recruiting --> Recruiting Completed --> Terminated; Sponsor decision not related to safety reasons
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial initiation date: A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Jan 4, 2017
P1, N=24, Recruiting, Sponsor: Sanofi
Completed --> Terminated; Sponsor decision not related to safety reasons Initiation date: Sep 2016 --> Jan 2017
- Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date: Effects of Victoza (clinicaltrials.gov) - Dec 1, 2016
P1, N=72, Active, not recruiting, Sponsor: Profil Institut f
Initiation date: Sep 2016 --> Jan 2017 Trial primary completion date: Oct 2016 --> Mar 2017
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: Px-Lixi: The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=24, Completed, Sponsor: University Hospital, Gentofte, Copenhagen
Trial primary completion date: Oct 2016 --> Mar 2017 Enrolling by invitation --> Completed
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P4 trial: LixiRam: Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan (clinicaltrials.gov) - Oct 20, 2016
P4, N=236, Not yet recruiting, Sponsor: Sanofi
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open, Trial initiation date: A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Sep 6, 2016
P1, N=24, Recruiting, Sponsor: Sanofi
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Sep 2016
- Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed, Trial primary completion date: Effects of Victoza (clinicaltrials.gov) - Aug 2, 2016
P1, N=72, Active, not recruiting, Sponsor: Profil Institut f
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Oct 2016
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P1 trial: A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM) (EUDRACT) - Jul 8, 2016
P1, N=28, , Sponsor: SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P1 trial: A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Jun 18, 2016
P1, N=24, Not yet recruiting, Sponsor: Sanofi
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment change: Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes (clinicaltrials.gov) - Jun 5, 2016
P4, N=8, Completed, Sponsor: University of Surrey
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Oct 2016 N=12 --> 8
- |||||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: LIXILAN JP-O1: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (clinicaltrials.gov) - May 22, 2016
P3, N=318, Recruiting, Sponsor: Sanofi
N=12 --> 8 Not yet recruiting --> Recruiting
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi, Apidra (insulin glulisine) / Sanofi
Biomarker, Trial completion: ELIXIRS: Effect of LIXIsenatide on the Renal System (clinicaltrials.gov) - May 2, 2016
P4, N=40, Completed, Sponsor: VU University Medical Center
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P3 trial: LIXILAN JP-O1: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (clinicaltrials.gov) - Apr 25, 2016
P3, N=318, Not yet recruiting, Sponsor: Sanofi
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New trial: Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=30, Recruiting, Sponsor: Seoul National University Hospital
- Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date: Effects of Victoza (clinicaltrials.gov) - Feb 24, 2016
P1, N=72, Recruiting, Sponsor: Profil Institut f
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion, Trial primary completion date: Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes (clinicaltrials.gov) - Feb 17, 2016
P4, N=12, Completed, Sponsor: University of Surrey
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Jan 2016
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New trial: Px-Lixi: The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=24, Enrolling by invitation, Sponsor: University Hospital, Gentofte, Copenhagen
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: Study on Lixisenatide and Counterregulation to Hypoglycemia (clinicaltrials.gov) - Dec 15, 2015
P4, N=18, Completed, Sponsor: Lund University
Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Jan 2016 Active, not recruiting --> Completed
- |||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion, Combination therapy: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine (clinicaltrials.gov) - Nov 16, 2015
P4, N=128, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Completed
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date: Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People (clinicaltrials.gov) - Oct 29, 2015
P1/2, N=30, Recruiting, Sponsor: Royal Adelaide Hospital
Recruiting --> Completed Trial primary completion date: Jun 2015 --> Apr 2016
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date: Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes (clinicaltrials.gov) - Oct 6, 2015
P4, N=12, Recruiting, Sponsor: University of Surrey
Trial primary completion date: Jun 2015 --> Apr 2016 Trial primary completion date: Jun 2015 --> Apr 2016
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion, Combination therapy: LixiBIT: Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin (clinicaltrials.gov) - Sep 24, 2015
P3, N=10, Completed, Sponsor: Medical University of Vienna
Trial primary completion date: Jun 2015 --> Apr 2016 Recruiting --> Completed
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion, Enrollment change, Trial primary completion date: Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients (clinicaltrials.gov) - Aug 27, 2015
P2, N=2, Completed, Sponsor: Sanofi
Recruiting --> Completed Active, not recruiting --> Completed | N=36 --> 2 | Trial primary completion date: Feb 2016 --> Aug 2015
- ||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion, Combination therapy: Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes (clinicaltrials.gov) - Aug 11, 2015
P3, N=294, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed | N=36 --> 2 | Trial primary completion date: Feb 2016 --> Aug 2015 Active, not recruiting --> Completed
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed: Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients (clinicaltrials.gov) - Aug 11, 2015
P2, N=36, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P4 trial: EGLIPA: The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) (clinicaltrials.gov) - Jul 17, 2015
P4, N=40, Recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
- ||||||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: LixiLan-O: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (clinicaltrials.gov) - Jun 17, 2015
P3, N=1170, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin (clinicaltrials.gov) - Jun 15, 2015
P3, N=447, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients (clinicaltrials.gov) - May 22, 2015
P2, N=36, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: GetGoal-O: Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (clinicaltrials.gov) - Apr 15, 2015
P3, N=350, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion, Monotherapy: Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes (clinicaltrials.gov) - Apr 9, 2015
P3, N=361, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed: LixiLan-O: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (clinicaltrials.gov) - Mar 24, 2015
P3, N=1125, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date, Combination therapy: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine (clinicaltrials.gov) - Mar 12, 2015
P4, N=148, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Oct 2015
- Enrollment open, Trial primary completion date: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=50, Recruiting, Sponsor: Erasme University Hospital
Trial primary completion date: Apr 2015 --> Oct 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Oct 2016
- ||||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: ELIXA: Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (clinicaltrials.gov) - Mar 11, 2015
P3, N=6075, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Oct 2016 Active, not recruiting --> Completed
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed: GetGoal-O: Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (clinicaltrials.gov) - Mar 7, 2015
P3, N=340, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open, Trial primary completion date: Effects of Victoza (clinicaltrials.gov) - Feb 27, 2015
P1, N=72, Recruiting, Sponsor: Profil Institut f
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Dec 2015
- || Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date, Combination therapy: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine (clinicaltrials.gov) - Feb 23, 2015
P4, N=148, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Jan 2015 --> Apr 2015
- | Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion, Enrollment change: Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying (clinicaltrials.gov) - Jan 22, 2015
P2, N=39, Completed, Sponsor: Profil Institut f
Trial primary completion date: Jan 2015 --> Apr 2015 Active, not recruiting --> Completed | N=26 --> 39
- ||||||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi, Apidra (insulin glulisine) / Sanofi
Trial completion: GetGoal Duo-2: Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (clinicaltrials.gov) - Jan 22, 2015
P3, N=894, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed | N=26 --> 39 Active, not recruiting --> Completed
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P1/2 trial: Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People (clinicaltrials.gov) - Dec 6, 2014
P1/2, N=30, Recruiting, Sponsor: Royal Adelaide Hospital
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed, Monotherapy: Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes (clinicaltrials.gov) - Dec 5, 2014
P3, N=360, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed: Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin (clinicaltrials.gov) - Dec 5, 2014
P3, N=432, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed, Combination therapy: Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes (clinicaltrials.gov) - Nov 28, 2014
P3, N=292, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Victoza (liraglutide) / Novo Nordisk
Trial completion: LIRA-LIXI (clinicaltrials.gov) - Nov 23, 2014
P4, N=404, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open, Trial initiation date, Combination therapy: LixiBIT: Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin (clinicaltrials.gov) - Nov 18, 2014
P3, N=10, Recruiting, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014
- | Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment closed: Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying (clinicaltrials.gov) - Nov 13, 2014
P2, N=26, Active, not recruiting, Sponsor: Profil Institut f
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 Enrolling by invitation --> Active, not recruiting
- |||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date: LixiLan-O: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (clinicaltrials.gov) - Nov 3, 2014
P3, N=1125, Recruiting, Sponsor: Sanofi
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Aug 2015 --> May 2015